Physician profile
Robert Lee Ensley
NPI 1619317302
$37,998.55
in general payments reported to CMS, 2019-2025
26 companies · $4,020 in 2025
The $4,020 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,675 · 2020: $10K · 2021: $1,473 · 2022: $12K · 2023: $1,531 · 2024: $4,863 · 2025: $4,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,090 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Travel and Lodging: $1,224 · Gift: $700 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Travel and Lodging | $1,224.49 |
| Gift | $700.00 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $10,872.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $9,044.14 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Coopervision INC. | $7,505.97 | 2019-2025 | Synergeyes Contact Lens, Onefit Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $3,034.60 | 2019-2025 | Total30, Hydrus Microstent, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $2,280.95 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $1,346.02 | 2024-2025 | Xdemvy |
| Visioneering Technologies, INC. | $790.04 | 2024-2025 | |
| Visionary Optics LLC | $700.00 | 2023 | |
| Sun Pharmaceutical Industries INC. | $367.64 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $274.47 | 2019-2023 | |
| Shire North American Group INC | $259.45 | 2019 | |
| Lkc Technologies, INC. | $251.92 | 2024 | |
| Allergan, INC. | $213.93 | 2019-2022 | |
| Glaukos Corporation | $208.15 | 2022-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $165.27 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $116.99 | 2019 | |
| Ivantis, INC | $100.20 | 2020 | |
| Thea Pharma INC. | $97.08 | 2023 | |
| Abbvie INC. | $95.83 | 2023 | |
| Harrow Eye, LLC | $79.45 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $52.73 | 2024-2025 | Tyrvaya |
| Biotissue Holdings INC. | $51.44 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $34.99 | 2023 | Acthar |
| Dompe US, INC. | $19.66 | 2024 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Synergeyes, INC. | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.